Company intelligence / Profile preview

Pharmadax Genesis

Jiaxing, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Pharmadax Genesis is developing a pipeline of drugs for molecular imaging diagnostics and radiopharmaceutical therapy, with a focus on targeted molecule screening, radiolabeling, and combining proximal therapy with immunotherapy. The company has raised significant funding to advance its programs targeting solid tumors. Specific clinical results have not been disclosed publicly as of June 2025

Therapeutic areas: Oncology
Modalities: Small moleculeRadiopharmaceuticalCombination therapy (radiolabeled drugs + immunotherapy)
Industry: Biotech

Partnerships

HTA.co (for development/commercialization of PMD‑12 against solid tumor)

Beyond the preview

Go deeper on Pharmadax Genesis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharmadax Genesis.

Explore the full profile